What's Happening?
Orsini, a leader in rare disease pharmacy solutions, has been named the single-source specialty pharmacy partner for Glaukos' Epioxa, a novel treatment for keratoconus. Epioxa, approved by the FDA in October 2025, offers a non-invasive alternative to traditional
corneal cross-linking procedures. This oxygen-enriched topical therapy, activated by UV light, aims to reduce pain and recovery time while providing significant clinical benefits. Keratoconus, a progressive eye disease, can lead to severe vision impairment and is a leading cause of corneal transplants in the U.S.
Why It's Important?
The partnership between Orsini and Glaukos represents a significant advancement in the treatment of keratoconus, offering patients a less invasive and more effective option. This collaboration highlights the importance of innovative therapies in addressing rare diseases and improving patient outcomes. The availability of Epioxa through Orsini's specialty pharmacy services ensures that patients have access to cutting-edge treatments, potentially reducing the need for more invasive procedures like corneal transplants.
What's Next?
Orsini and Glaukos will likely focus on expanding access to Epioxa and educating healthcare providers about its benefits. The success of this partnership could encourage further collaborations in the rare disease space, promoting the development and distribution of innovative therapies. Monitoring patient outcomes and gathering real-world data will be crucial in demonstrating the long-term efficacy and safety of Epioxa.
